AirSculpt Technologies Reports Third Quarter Fiscal 2026 Results

Quarterly operating cash outflow widened to $3.475 million from $225,000 a year earlier.

Rhea-AI Summary

AirSculpt Technologies (AIRS) reported third-quarter revenue of $31.9 million and lowered its full-year outlook as procedure volumes declined. Revenue fell 8.7% year over year, while same-center cases decreased 9.6%. Net loss narrowed to $7.173 million from $9.512 million, but adjusted EBITDA, a non-GAAP earnings measure, fell to $393,000 from $3.039 million.

For the first nine months, revenue declined 3.5% to $114.2 million. AirSculpt now expects approximately $144 million–$146 million in 2026 revenue and approximately $9 million–$10 million in adjusted EBITDA, below its previous ranges. On November 5, it completed refinancing with a $39.0 million funded senior secured term loan and an undrawn revolving facility of up to $5.0 million, maturing November 5, 2031. September 30 cash was $15.182 million; third-quarter operating cash outflow was $3.475 million.

11 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

2 major · 16 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointRefinancing completed with a $39.0 million funded term loan and maturity extended to November 5, 2031. 38% of market cap
• Moderate pointThird-quarter at-the-market offering raised an additional $7.2 million. 6.9% of market cap
• Moderate pointThird-quarter debt repayments totaled $7.0 million. 6.7% of market cap
• Moderate pointAsset impairment losses fell to $5,000 quarterly and year-to-date, from $7.137 million and $7.245 million.
• Minor pointNew revolving facility provides up to $5.0 million, undrawn at closing.

6 minor points

• Minor pointThird-quarter net loss narrowed to $7.173 million from $9.512 million; loss per share improved to $0.10 from $0.15.
• Minor pointNine-month net loss narrowed to $10.682 million from $12.950 million; loss per share improved to $0.15 from $0.22.
• Minor pointThird-quarter same-center revenue per case increased 2.3% to $12,865 from $12,574.
• Minor pointCash increased to $15.182 million at September 30, 2026, from $8.449 million at December 31, 2025.
• Minor pointCost of service fell to $12.914 million quarterly and $45.069 million year-to-date, from $14.864 million and $48.015 million.
• Minor pointNet interest expense fell to $1.244 million quarterly and $3.485 million year-to-date, from $1.407 million and $4.594 million.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.2026 revenue guidance reduced to approximately $144 million–$146 million, from $151 million–$157 million.
• Major pointRefinancing creates a $39.0 million senior secured term-loan obligation, replacing the previous credit agreement. 38% of market cap
• Moderate pointThird-quarter revenue declined 8.7% year over year to $31.9 million.
• Moderate pointThird-quarter same-center case volume decreased 9.6% year over year to 2,483.
• Moderate pointThird-quarter adjusted EBITDA fell to $393,000 from $3.039 million; margin declined to 1.2% from 8.7%.
• Moderate pointNine-month revenue declined 3.5% year over year to $114.2 million.
• Moderate pointThird-quarter operating cash outflow widened to $3.475 million from $225,000 a year earlier.
• Moderate pointThird-quarter at-the-market share issuance diluted existing holders.

8 minor points

• Minor point. Forward-looking: it has not happened yet and may not happen.2026 adjusted EBITDA guidance reduced to approximately $9 million–$10 million, from $12 million–$14 million.
• Minor pointNine-month same-center case volume decreased 2.1% year over year to 8,941.
• Minor pointNine-month adjusted EBITDA fell to $8.640 million from $12.629 million; margin declined to 7.6% from 10.7%.
• Minor pointNine-month operating cash inflow declined to $558,000 from $5.627 million a year earlier.
• Minor pointSelling, general and administrative expenses rose to $20.262 million quarterly and $66.265 million year-to-date, from $19.525 million and $63.964 million.
• Minor pointThird-quarter income taxes shifted to $1.789 million expense from a $1.645 million benefit.
• Minor pointNine-month income taxes shifted to $1.223 million expense from a $2.197 million benefit.
• Minor pointOne-time financial-reporting compliance and related costs reached $497,000 quarterly and $1.543 million year-to-date.

News Explained

In Q3, AirSculpt raised $7.2 million through its at-the-market program and paid down $7.0 million of debt; the program sells new shares gradually, increasing share count and reducing existing holders’ ownership percentages absent offsets.

Key Figures

Q3 revenue: $31.9M; down 8.7% from $35.0M Q3 cases: 2,483; down 9.6% Q3 net loss: $7.2M; improved by $2.3M from $9.5M +5 more

Q3 revenue

$31.9M; down 8.7% from $35.0M

Third quarter fiscal 2026 versus fiscal 2025

Q3 cases

2,483; down 9.6%

Same-store basis versus prior year

Q3 net loss

$7.2M; improved by $2.3M from $9.5M

Third quarter fiscal 2026 versus fiscal 2025

Q3 Adjusted EBITDA

$0.4M; down $2.6M from $3.0M

Third quarter fiscal 2026 versus fiscal 2025

FY2026 revenue guidance

$144M–$146M

Reduced from the previous range of $151M–$157M

FY2026 Adjusted EBITDA guidance

$9M–$10M

Reduced from the previous range of $12M–$14M

Senior secured term loan

$39.0M

Funded in full at closing; matures November 5, 2031

Revolving loan commitment

Up to $5.0M

None drawn at closing

Historical Context

1 past event · Latest: Aug 10

1 event

1. Aug 10

   Q2 earnings report

   24h Move

   -45.1%

   Q2 revenue fell, Adjusted EBITDA declined, and the company cut EBITDA guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

glp-1, at-the-market offering program, senior secured, revolving loan facility

4 terms

glp-1 medical

"Performed approximately 250 GLP-1-related procedures during the quarter"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

at-the-market offering program financial

"raised an additional $7.2 million from the at-the-market offering program"

An at-the-market offering program lets a company sell newly issued shares directly into the open market at current trading prices through a broker, rather than issuing a large block of stock all at once. It matters to investors because it provides the company a flexible way to raise cash over time, which can dilute existing shares gradually and affect earnings per share and stock price depending on how much and when shares are sold—think of it as a faucet the company can open or close to add supply to the market.

senior secured financial

"consisting of a senior secured (i) term loan facility"

Senior secured describes a loan or bond that has first claim on a company’s assets and is backed by specific collateral, like a mortgage on property. For investors, that means they are paid before other creditors if the company struggles or is liquidated, reducing the chance of loss compared with unsecured or junior debt. Think of it as a front-of-the-line, collateral-backed claim that typically carries lower interest because of that added protection.

revolving loan facility financial

"and (ii) revolving loan facility with an aggregate commitment"

A revolving loan facility is a flexible credit line a company can draw from, repay, and draw again as needed, similar to a business-sized credit card. It matters to investors because it provides short-term cash for operations, acquisitions, or unexpected expenses without issuing new shares, and its size, cost, and terms signal a company’s liquidity, borrowing capacity and financial resilience under stress.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Completes Term Loan Refinancing, Extending Maturity to 2031

TAMPA, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the third quarter ended September 30, 2026.

Yogi Jashnani, Chief Executive Officer, stated: "While our third quarter results were below expectations, we identified the key drivers and are addressing them with a sense of urgency. Importantly the quarter saw strong progress on our priorities, including expanding our GLP-1-related procedures. Following quarter end, we marked a key milestone as we completed the refinance of our term loan - extending our debt maturity to 2031. While we have reduced our guidance to reflect our third quarter performance continuing through year-end, we remain confident in our strategy and our ability to deliver sustainable, profitable long-term growth."

Third Quarter 2026 Results

• Revenue was $31.9 million, a decline of 8.7% from $35.0 million in the fiscal year 2025;
• Case volume was 2,483, a 9.6% decrease on a same-store sales basis versus the prior year;
  • Performed approximately 250 GLP-1-related procedures during the quarter, representing approximately 10% of total cases
• Net loss was $7.2 million, an improvement of $2.3 million from a net loss of $9.5 million in the fiscal year 2025 third quarter; and
• Adjusted EBITDA was $0.4 million, a decline of $2.6 million, compared to $3.0 million in the fiscal year 2025 third quarter.
  
  

First Nine Months 2026 Results

• Revenue was $114.2 million, a decline of  3.5% from $118.4 million in the first nine months of fiscal year 2025;
• Case volume was 8,941, a 2.1%  decrease on a same-store sales basis versus the prior year;
• Net loss was $10.7 million, an improvement of $2.3 million  from a net loss of $13.0 million  in the first nine months of fiscal year 2025; and
• Adjusted EBITDA was $8.6 million, a decline of $4 million, compared to $12.6 million in the first nine months of fiscal year 2025.
  
  

2026 Outlook

The Company is reducing its full-year 2026 revenue and Adjusted EBITDA guidance as follows:

• Revenue in the range of approximately $144 million to $146 million, compared to the previous range of $151 million to $157 million; and
• Adjusted EBITDA in the range of approximately $9 million to $10 million, compared to the previous range of $12 million to $14 million.
  
  

For additional information on forward-looking statements, see the section titled "Forward-Looking Statements" below.

Debt & Liquidity

As of September 30, 2026, the Company had $15.2 million in cash and cash equivalents, with $5.0 million of borrowing capacity under its revolving credit facility. Additionally, gross debt was approximately $37.2 million. During the 2026 third quarter, the Company raised an additional $7.2 million from the at-the-market offering program and paid down $7.0 million of debt.

On November 5, 2026, the Company entered into a financing agreement (the "Blue Torch Financing Agreement") with a syndicate of lenders and Blue Torch Finance LLC, as administrative agent and collateral agent, maturing on November 5, 2031 and consisting of a senior secured (i) term loan facility with an aggregate principal amount of $39.0 million, which was funded in full at closing, and (ii) revolving loan facility with an aggregate commitment of up to $5.0 million, none of which was drawn at closing. Proceeds from the Blue Torch Financing Agreement were used to repay in full all indebtedness under, and terminate, the Company's existing credit agreement and to pay fees and expenses related to the Blue Torch Financing Agreement.

Conference Call Information

AirSculpt will hold a conference call today, November 6, 2026 at 8:30 am (Eastern Time). The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13763463 or by visiting the link below to request a return call for instant telephone access to the event.

https://callme.viavid.com/viavid/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9MTM3MjUxMTYmaD10cnVlJmluZm89Y29tcGFueSZyPXRydWUmQj02

The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.airsculpt.com. A replay of the webcast will be available for approximately 90 days following the call.

To learn more about AirSculpt, please visit the Company's website at https://investors.airsculpt.com. AirSculpt uses its website as a channel of distribution for material Company information. Financial and other material information regarding AirSculpt is routinely posted on the Company's website and is readily accessible.

About AirSculpt

AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal U.S. securities laws. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology, but the absence of  these words does not mean that a statement is not forward-looking. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include projections of our future financial performance (including in particular our projected 2026 revenue and adjusted EBITDA), our anticipated growth strategies, and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. You are cautioned that there are important risks and uncertainties, many of which are beyond our control, that could cause our actual results, level of activity, performance, or achievements to differ materially from the projected results, level of activity, performance or achievements that are expressed or implied by such forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements, including those factors discussed in the section titled “Risk Factors” in our Annual Report on Form 10-K.

Our future results could be affected by a variety of other factors, including, but not limited to, inability to sell equity or other securities in the future at a time when we might otherwise wish to effect sales; inability to raise capital on commercially reasonable terms, if at all; our ability to comply with the financial maintenance covenants and other requirements of the Blue Torch Financing Agreement, including its mandatory prepayment requirements; limitations on our ability to sell securities under our shelf registration statement;  the risk that any future financings may dilute our stockholders or restrict our business; failure to stabilize and grow same-store performance; not being able to optimize our marketing investment, go-to-market strategy and sales process; not having the ability to expand our financing options for consumers; being unsuccessful in further product innovations; failure to operate centers in a cost-effective manner; increased operating expenses due to rising inflation; increased competition in the weight loss and obesity solutions market, including as a result of the recent regulatory approval, increased market acceptance, availability and customer awareness of weight-loss drugs; shortages or quality control issues with third-party manufacturers or suppliers; competition for surgeons; litigation or medical malpractice claims; inability to protect the confidentiality of our proprietary information; changes in the laws governing the corporate practice of medicine or fee-splitting; changes in regulatory and macroeconomic conditions, including inflation and the threat of recession, economic and other conditions of the states and jurisdictions where our facilities are located; and business disruption or other losses from natural disasters, war, pandemic, terrorist acts or political unrest.

The risk factors discussed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K and in other filings we make from time to time with the SEC could cause our results to differ materially from those expressed in the forward-looking statements made in this press release.

There also may be other risks and uncertainties that are currently unknown to us or that we are unable to predict at this time.

Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Forward-looking statements represent our estimates and assumptions only as of the date they were made, which are inherently subject to change, and we are under no duty and we assume no obligation to update any of these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated after the date of this press release to conform our prior statements to actual results or revised expectations, except as required by law. Given these uncertainties, investors should not place undue reliance on these forward-looking statements.

Use of Non-GAAP Financial Measures

The Company reports financial results in accordance with generally accepted accounting principles in the United States (“GAAP”), however, the Company believes the evaluation of ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Loss and Adjusted Net Loss per Share, which are non-GAAP financial measures. Although the Company provides guidance for Adjusted EBITDA, it is not able to provide guidance for net income, the most directly comparable GAAP measure. Certain elements of the composition of net income, including equity-based compensation, are not predictable, making it impractical for us to provide guidance on net income or to reconcile our Adjusted EBITDA guidance to net income without unreasonable efforts. For the same reasons, the Company is unable to address the probable significance of the unavailable information regarding net income, which could be material to future results.

These non-GAAP financial measures are not intended to replace financial performance measures determined in accordance with GAAP. Rather, they are presented as supplemental measures of the Company's performance that management believes may enhance the evaluation of the Company's ongoing operating results. These non-GAAP financial measures are not presented in accordance with GAAP, and the Company’s computation of these non-GAAP financial measures may vary from similar measures used by other companies. These measures have limitations as an analytical tool and should not be considered in isolation or as a substitute or alternative to revenue, net income, operating income, cash flows from operating activities, total indebtedness or any other measures of operating performance, liquidity or indebtedness derived in accordance with GAAP.

AirSculpt Technologies, Inc. and Subsidiaries Selected Consolidated Financial Data (Dollars in thousands, except shares and per share amounts)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Revenue	$	31,944			$	34,993			$	114,233			$	118,376
Operating expenses:
Cost of service		12,914				14,864				45,069				48,015
Selling, general and administrative		20,262				19,525				66,265				63,964
Depreciation and amortization		2,902				3,217				8,864				9,705
Loss on impairment of long-lived assets		5				7,137				5				7,245
Total operating expenses		36,083				44,743				120,203				128,929
(Loss)/income from operations		(4,139	)			(9,750	)			(5,970	)			(10,553	)
Interest expense, net		1,244				1,407				3,485				4,594
Unrealized loss		1				—				4				—
Pre-tax net loss		(5,384	)			(11,157	)			(9,459	)			(15,147	)
Income tax expense/(benefit)		1,789				(1,645	)			1,223				(2,197	)
Net loss	$	(7,173	)		$	(9,512	)		$	(10,682	)		$	(12,950	)
Loss per share of common stock
Basic	$	(0.10	)		$	(0.15	)		$	(0.15	)		$	(0.22	)
Diluted	$	(0.10	)		$	(0.15	)		$	(0.15	)		$	(0.22	)
Weighted average shares outstanding
Basic		72,538,877				62,436,670				70,943,909				60,202,169
Diluted		72,538,877				62,436,670				70,943,909				60,202,169

AirSculpt Technologies, Inc. and Subsidiaries Selected Financial and Operating Data (Dollars in thousands, except per case amounts)
	September 30, 2026				December 31, 2025
Balance Sheet Data (at period end):
Cash and cash equivalents	$	15,182			$	8,449
Total current assets		23,051				15,456
Total assets	$	187,776			$	187,304
Current portion of long-term debt	$	5,460			$	5,460
Deferred revenue and patient deposits		3,345				1,871
Total current liabilities		27,208				27,902
Long-term debt, net		31,199				50,585
Total liabilities	$	81,840			$	99,592
Total stockholders’ equity	$	105,936			$	87,712

	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Cash Flow Data:
Net cash provided by (used in):
Operating activities	$	(3,475	)		$	(225	)		$	558			$	5,627
Investing activities		(226	)			(180	)			(505	)			(2,346	)
Financing activities		59				(2,379	)			6,680				(6,111	)

	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Other Data:
Number of facilities		31				32				31				32
Number of total procedure rooms		65				67				65				67
Cases		2,483				2,780				8,941				9,248
Revenue per case	$	12,865			$	12,587			$	12,776			$	12,800
Adjusted EBITDA(1)	$	393			$	3,039			$	8,640			$	12,629
Adjusted EBITDA margin(2)		1.2	%			8.7	%			7.6	%			10.7	%

⁽¹⁾ A reconciliation of this non-GAAP financial measure appears below.
⁽²⁾ Defined as Adjusted EBITDA as a percentage of revenue.

	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Same-center Information(1):
Cases		2,483				2,748				8,941				9,137
Case growth	(9.6		)%		N/A				(2.1		)%		N/A
Revenue per case	$	12,865			$	12,574			$	12,776			$	12,777
Revenue per case growth		2.3	%		N/A					—	%		N/A
Number of facilities		31				31				31				31
Number of total procedure rooms		65				65				65				65

⁽¹⁾   For the three and nine months ended September 30, 2026 and 2025, we define same-center case and revenue growth as the growth in each of our cases and revenue at facilities that were owned and operated during the three and nine months ended September 30, 2026 and 2025, respectively. At facilities that were not owned or operated for the entirety of the prior year period, the current year period has been pro-rated to reflect only growth experienced during the portion of the three and nine months ended September 30, 2026 in which such facilities were owned and operated during the three and nine months ended September 30, 2025. We define same-center facilities and procedure rooms based on if a facility was owned or operated as of September 30, 2025.  We have excluded the London facility from all periods presented due to the closure of the facility.

We report our financial results in accordance with GAAP, however, management believes the evaluation of our ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Loss and Adjusted Net Loss per Share, which are non-GAAP financial measures.

We define Adjusted EBITDA as net loss excluding depreciation and amortization, net interest expense, income tax expense/(benefit), restructuring and related severance costs, certain other non-recurring costs, unrealized (gain)/loss, and equity-based compensation.

We define Adjusted Net Loss as net loss excluding restructuring and related severance costs, loss on impairment of long-lived assets, certain other non-recurring costs, equity-based compensation and the tax effect of these adjustments.

We include Adjusted EBITDA and Adjusted Net Loss because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA and Adjusted Net Loss each to be an important measure because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. Adjusted EBITDA has limitations as an analytical tool including: (i) Adjusted EBITDA does not include results from equity-based compensation and  (ii) Adjusted EBITDA does not reflect interest expense on our debt or the cash requirements necessary to service interest or principal payments. Adjusted Net Loss has limitations as an analytical tool because it does not include results from equity-based compensation.

We define Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of revenue.  We define Adjusted Net Loss per Share as Adjusted Net Loss divided by weighted average basic and diluted shares. We included Adjusted EBITDA Margin and Adjusted Net Loss per Share because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA Margin and Adjusted Net Loss per Share to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis.

The following table reconciles Adjusted EBITDA and Adjusted EBITDA Margin to net loss, the most directly comparable GAAP financial measure:

	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Net loss	$	(7,173	)		$	(9,512	)		$	(10,682	)		$	(12,950	)
Plus													​
Equity-based compensation		1,095				1,125				2,566				3,716
Restructuring and related severance costs		33				1,310				1,307				2,516
One-time SOX compliance and other related costs		497				—				1,543				—
Depreciation and amortization		2,902				3,217				8,864				9,705
Loss on impairment of long-lived assets		5				7,137				5				7,245
Litigation settlements		—				—				325				—
Interest expense, net		1,244				1,407				3,485				4,594
Income tax expense/(benefit)		1,789				(1,645	)			1,223				(2,197	)
Unrealized loss		1				—				4				—
Adjusted EBITDA	$	393			$	3,039			$	8,640			$	12,629
Adjusted EBITDA Margin		1.2	%			8.7	%			7.6	%			10.7	%

The following table reconciles Adjusted Net Loss and Adjusted Net Loss per Share to net loss, the most directly comparable GAAP financial measure:

	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Net loss	$	(7,173	)		$	(9,512	)		$	(10,682	)		$	(12,950	)
Plus
Equity-based compensation		1,095				1,125				2,566				3,716
Restructuring and related severance costs		33				1,310				1,307				2,516
Loss on impairment of long-lived assets		5				7,137				5				7,245
Litigation settlements		—				—				325				—
One-time SOX compliance and other related costs		497				—				1,543				—
Tax effect of adjustments		(565	)			(2,462	)			(1,385	)			(2,850	)
Adjusted net (loss)/income	$	(6,108	)		$	(2,402	)		$	(6,321	)		$	(2,323	)
Adjusted net loss per share of common stock(1)
Basic	$	(0.08	)		$	(0.04	)		$	(0.09	)		$	(0.04	)
Diluted	$	(0.08	)		$	(0.04	)		$	(0.09	)		$	(0.04	)
Weighted average shares outstanding
Basic		72,538,877				62,436,670				70,943,909				60,202,169
Diluted		72,538,877				62,436,670				70,943,909				60,202,169

(1)   Diluted Adjusted Net Loss Per Share is computed by dividing adjusted net loss by the weighted-average number of shares of common stock outstanding adjusted for the dilutive effect of all potential shares of common stock.

Investor Contact
Allison Malkin
ICR, Inc.
airsculpt@icrinc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were AirSculpt's third-quarter 2026 earnings results?

AirSculpt reported $31.9 million in revenue, down 8.7% year over year, and a net loss of $7.173 million versus $9.512 million. Adjusted EBITDA declined to $393,000 from $3.039 million, while same-center case volume fell 9.6%.

What is AirSculpt's updated 2026 financial guidance?

AirSculpt expects approximately $144 million to $146 million in revenue and approximately $9 million to $10 million in adjusted EBITDA. The previous ranges were $151 million to $157 million and $12 million to $14 million, respectively.

Why did AirSculpt lower its 2026 outlook?

AirSculpt said the reduced outlook reflects its third-quarter performance continuing through year-end. Third-quarter results were below management's expectations.

How did AirSculpt use the proceeds from its November 2026 refinancing?

Refinancing proceeds repaid all indebtedness under the previous credit agreement and covered fees and expenses related to the new financing. The previous credit agreement was terminated. Blue Torch Finance serves as administrative agent and collateral agent for the new lender syndicate.

How many GLP-1-related procedures did AirSculpt perform in the third quarter of 2026?

AirSculpt performed approximately 250 GLP-1-related procedures during the quarter, representing approximately 10% of total cases.